Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome

Number of patients, n 27
Male sex, n (%) 18 (67)
Age (years) 63.9 ± 10.4
BMI (kg/m2) 28.8 ± 4.3
Tumor stage, n (%)
 IA 0
 IB 7 (26)
 IIA 5 (18)
 IIB 14 (52)
 III 1 (4)
 IV 0
Tumor Location, n (%)
 Head 18 (67)
 Body 3 (11)
 Tail 6 (22)
Preoperative biliary stent, n (%)
 No Stent 11 (41)
 Stent 16 (59)
 Stent type, n (%)  
  Plastic 7 (26)
  Metal 7 (26)
  Unknown 2 (7)
Neoadjuvant chemotherapy, n (%)
 None 17 (63)
 Gemcitabine 7 (26)
 Gemcitabine/Paclitaxel 2 (7)
 Gemcitabine/Oxaliplatin 1 (4)
Recent antibiotic exposure (<  6 weeks preoperatively)
 Yes 3 (11)
 No 24 (89)
Operative procedure, n (%)
 Pancreaticoduodenectomy (Whipple) 18 (67)
 Distal pancreatectomy and splenectomy 9 (33)
Perioperative antibiotic prophylaxis, n (%)
 Cefazolin 12 (44)
 Cefoxitin 7 (26)
 Cefotetan 5 (18)
 Clindamycin 1 (4)
 Levofloxacin 1 (4)
 Unknown 1 (4)
Infectious postoperative complications, n (%)
 None 19 (70)
 Superficial SSI 3 (11)
 Deep/organ-space SSI 2 (7)
 Pancreatic anastomotic leak 5 (18)
Clostridium difficile colitis 2 (7)
 Urinary tract infection 2 (7)
 Parotiditis 1 (4)
Survival, n (%)
 Short-term survival (<  5 years) 17 (63)
 Long-term survival (>  5 years) 3 (11)
 Lost to follow up 7 (26)
  1. Continuous data presented as mean ± standard deviation. BMI Body mass index, SSI Surgical site infection